Printer Friendly


 MISSISSAUGA, Ontario, Aug. 24 /PRNewswire/ -- Further results of the effectiveness of HYAL-AT2101, Hyal's topical pain formulation, were presented today at the Seventh World Pain Congress in Paris, Hyal Pharmaceutical Corporation (NASDAQ-NMS: HYALF) announced today.
 Dr. Leonard Rose, founder and principal of the Melbourne Pain Management Clinic in Australia, presented preliminary results from a group of 27 patients suffering from moderate to severe intractable pain resistant to other methods of pain management. He reported that more than 62 percent of patients experienced a decrease in pain and an improvement in function when treated with HYAL-AT2101. Of the non- responders, half were shown to have primary psychogenic (mental origin) pain disorders while the remainder had secondary gain factors.
 Dr. Rose also commented that another group of 40 patients reported pain reduction and improved function not previously achieved by oral anti-inflammatory/analgesic preparations or by physical therapy.
 The significance of these results is that no other topical NSAID preparation currently marketed has proven to be effective in the treatment of chronic intractable pain conditions. These results provide further evidence that Hyal's proprietary drug delivery technology is able to significantly improve the effectiveness of one of the world's most widely prescribed anti-inflammatory/analgesic drugs.
 Hyal specializes in the development and world wide commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronic Acid based drug delivery technology. Hyal is currently conducting Phase III clinical trials at 14 independent centers in Canada, the U.S.A., Australia and a number of European countries for its three lead products: HYAL-CT1101 for the treatment of basal cell carcinoma. HYAL- AT2101 for the topical treatment of pain and HYAL-AV2201 for the intravenous treatment of moderate to severe pain.
 Hyal Pharmaceutical Corporation's shares are traded on the Toronto Stock Exchange under the trading symbol HPC and on NASDAQ National Market System under the trading symbol HYALF.
 -0- 8/24/93
 /CONTACT: Samuel S. Asculai, president and CEO, 416-366-4863, or David W. Harper, vice president-development, 416-366-4863 both of Hyal Pharmaceutical Corporation; or Diane Perry, 212-661-8030, or Kathy Brunson, 312-266-7800, both of The Financial Relations Board/

CO: Hyal Pharmaceutical Corporation ST: Ontario IN: MTC SU:

TS -- NY030 -- 5393 08/24/93 10:42 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 24, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters